---
schema_version: "secwatch.filing_event.v1"
accession: "0000950142-24-002817"
form_type: "8-K"
ticker: "TCRX"
cik: "0001783328"
company_name: "TScan Therapeutics, Inc."
filed_at: "2024-11-21T23:59:59+00:00"
generated_at: "2026-05-29T21:01:55.767535+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# TScan converts $15M loan principal into 3.13M shares at $4.785

## Summary
- K2 HealthVentures converted $15M of convertible term loan into 3,134,796 voting common shares at $4.785/share.
- Shares issued November 20, 2024 under Section 3(a)(9) exemption; no registration statement required.
- Conversion reduces debt but dilutes existing stockholders by approximately 5.5% based on shares outstanding.

## SEC filing metadata
- accession: 0000950142-24-002817
- form_type: 8-K
- ticker: TCRX
- cik: 0001783328
- company_name: TScan Therapeutics, Inc.
- filed_at: 2024-11-21T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 3.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783328/000095014224002817/0000950142-24-002817-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783328/000095014224002817/eh240560212_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950142-24-002817
- JSON: https://secwatch.observer/filing/0000950142-24-002817.json
- Plain text: https://secwatch.observer/filing/0000950142-24-002817.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.